What is Syntermed?
Syntermed is a prominent entity in the medical imaging solutions market, with a specialized focus on developing sophisticated software tools. Their expertise spans nuclear cardiology, brain imaging, and PSMA PET/CT scans. Products such as NeuroQ and Cardiac Toolbox are designed to elevate the clinical value and decision-making capabilities for healthcare professionals by enhancing the accuracy and efficiency of medical imaging analysis. The company is dedicated to delivering cutting-edge solutions to healthcare providers and institutions that prioritize advanced imaging technologies.
How much funding has Syntermed raised?
Syntermed has raised a total of $277K across 2 funding rounds:
Debt
$150K
Debt
$127K
Debt (2020): $150K with participation from PPP
Debt (2021): $127K led by PPP
Key Investors in Syntermed
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Syntermed?
The substantial late-stage funding Syntermed has received signals a strategic phase of scaling and market expansion. This capital injection is likely to fuel further research and development into their advanced imaging software, potentially leading to new product launches or enhancements to existing platforms. The company's focus on improving diagnostic accuracy and operational efficiency in medical imaging positions it for continued influence within the healthcare technology landscape. Future developments may include broader adoption of their solutions across a wider network of healthcare facilities and potential strategic partnerships to enhance their market reach.
See full Syntermed company page
